To demonstrate the antitumor activity and safety of neoadjuvant pembrolizumab plus ramucirumab followed by surgery in patients with PD-L1 positive stage IB-IIIA non-small cell lung cancer
The efficacy and safety of the neoadjuvant therapy of pembrolizumab+ ramucirumab